Kidney transplant
Conditions
Interventions
Test group:Rosastat,oral
Control group:Injection of erythropoietin
Sponsors
Renji Hospital affiliated to Shanghai Jiao Tong University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) 18-65 years old; 2) There are indications for kidney transplantation, and kidney transplantation is performed in three kidney transplantation centers; 3) The patients were diagnosed as renal anemia according to the Chinese clinical practice guide for the diagnosis and treatment of renal anemia (2021 Edition); ? Anemia is confirmed: hemoglobin (HB) of male is less than 130 g/l, and Hb of female is less than 120 g / L ? Ischemic or hemorrhagic diseases other than renal anemia are excluded, including dystrophic anemia, hemolytic anemia, hemorrhagic anemia, and blood system diseases 4) Patients' postoperative prescription data were complete; 5) Sign the informed consent form; 6) Regular follow-up; 7) Normal liver function; 8) Weight 40-100kg (included) 9) The subjects must agree not to use any new anemia drugs from the beginning of enrollment to the end of the follow-up period, nor change the dose, administration plan or brand of any anemia drugs used before enrollment.
Exclusion criteria
Exclusion criteria: 1) Combined multiple organ transplantation; 2) Those who use drugs in combination outside the specified range, especially those that have a great impact on the test results, such as intravenous iron, blood transfusion, etc., which affect the judgment of effectiveness and safety; 3) Participants in other clinical trials; 4) Previous history of other organ transplantation; 5) Failing to sign the informed consent; 6) Any clinically significant infection or active tumor, evidence of infection (including bacteria and viruses); 7) Chronic liver disease; 8) Patients who are expected to need blood transfusion; 9) Pregnant and lactating women; 10) The expected life is less than 12 months; Other circumstances that the researcher believes are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scr;Hb;BUN;Urine protein; | — |
Secondary
| Measure | Time frame |
|---|---|
| Red blood cell count;Fe;eticulocyte count;ALT;AST;Direct bilirubin;total bilirubin;uric acid;LDL;HDL;TG;Incidence of rejection reactions and infections; | — |
Countries
China
Contacts
Public ContactZhang Ming
Renji Hospital affiliated to Shanghai Jiao Tong University Medical College
Outcome results
None listed